The United States sent Gilead Sciences’ remdesivir and Mapp Biopharmaceutical Inc.’s experimental Ebola antibody drug MBP134 to Uganda last week to help safeguard healthcare workers responding to an outbreak that has infected 60 people and killed 44, U.S. government sources told Reuters.